Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Guardant Health Inc (GH)

Guardant Health Inc (GH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,916,276
  • Shares Outstanding, K 93,906
  • Annual Sales, $ 90,640 K
  • Annual Income, $ -85,060 K
  • 60-Month Beta 0.23
  • Price/Sales 43.34
  • Price/Cash Flow N/A
  • Price/Book 9.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.28
  • Low Estimate -0.34
  • Prior Year -0.30
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.89 +15.21%
on 01/31/20
86.00 -1.01%
on 02/18/20
+0.53 (+0.63%)
since 01/17/20
3-Month
70.71 +20.39%
on 12/11/19
86.65 -1.75%
on 01/17/20
+6.34 (+8.05%)
since 11/18/19
52-Week
49.46 +72.12%
on 02/19/19
112.21 -24.14%
on 08/08/19
+34.06 (+66.69%)
since 02/15/19

Most Recent Stories

More News
Alkermes' (ALKS) Earnings and Revenues Beat Estimates in Q4

Alkermes (ALKS) beats earnings and sales estimates in the fourth quarter of 2019.

BIIB : 337.10 (+1.23%)
JNJ : 149.14 (-0.66%)
ALKS : 17.61 (-0.90%)
GH : 85.13 (+0.98%)
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4

Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

BAYRY : 20.3600 (-3.14%)
RARE : 61.10 (-0.05%)
AVXL : 5.81 (+16.20%)
GH : 85.13 (+0.98%)
Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA

Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.

ONCY : 2.53 (-2.32%)
TRVN : 0.75 (-3.81%)
AVXL : 5.81 (+16.20%)
GH : 85.13 (+0.98%)
Should Growth Investors Buy this Cancer Screening Biotech Stock?

Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?

RGEN : 106.00 (+0.03%)
EXAS : 99.60 (+1.45%)
MRNA : 18.91 (-0.47%)
GH : 85.13 (+0.98%)
Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?

Is (GH) Outperforming Other Medical Stocks This Year?

GH : 85.13 (+0.98%)
Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.

BDSI : 5.32 (+0.95%)
ALXN : 102.16 (-0.39%)
GH : 85.13 (+0.98%)
DNLI : 26.21 (+3.11%)
Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation

Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.

BDSI : 5.32 (+0.95%)
GILD : 67.01 (-0.81%)
GH : 85.13 (+0.98%)
DNLI : 26.21 (+3.11%)
Guardant Health (GH) Dips More Than Broader Markets: What You Should Know

Guardant Health (GH) closed the most recent trading day at $80.04, moving -1.82% from the previous trading session.

GH : 85.13 (+0.98%)
Guardant Health (GH) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Guardant Health (GH) closed at $80.59, marking a +0.93% move from the previous day.

GH : 85.13 (+0.98%)
Jazz Enrolls First Patient in Phase II/III Leukemia Study

Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

INVA : 15.08 (+0.07%)
JAZZ : 136.83 (-2.85%)
ACRX : 1.56 (-2.50%)
GH : 85.13 (+0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade GH with:

Business Summary

Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption,...

See More

Key Turning Points

2nd Resistance Point 87.39
1st Resistance Point 86.26
Last Price 85.13
1st Support Level 83.74
2nd Support Level 82.35

See More

52-Week High 112.21
Fibonacci 61.8% 88.24
Last Price 85.13
Fibonacci 50% 80.84
Fibonacci 38.2% 73.43
52-Week Low 49.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar